Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Mayne Pharma (MYX AU): Scheme Booklet Dispatch Lends More Than A Veneer Of Support

Mayne Pharma (MYX AU): Firm Support From Cosette Would Be Welcome About Now

Quiddity Advisors

Event-Driven

<ul>
<li>In a watershed decision, the Supreme Court of NSW ruled Cosette cannot terminate its Scheme for <strong><a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a></strong>.</li>
<li>The hearings were the first time a material adverse change clause had been considered by an Australian court under such circumstances.</li>
<li>The transaction still requires FIRB signing off. Concerns linger over whether Cosette intends to close a South Australian plant. Mayne has previously dispelled these concerns. </li>
</ul>


In a watershed decision, the Supreme Court of NSW ruled Cosette cannot terminate its Scheme for Mayne Pharma (MYX AU).
The hearings were the first time a material adverse change clause had been considered by an Australian court under such circumstances.
The transaction still requires FIRB signing off. Concerns linger over whether Cosette intends to close a South Australian plant. Mayne has previously dispelled these concerns. 


Mayne Pharma (MYX AU): Court Rules Cosette Cannot Walk